Impact of GP IIb/IIIa antagonists in interventional cardiology;Bedeutung von GP IIb/IIIa-rezeptor-antagonisten in der invasiven kardiologie

Deutsche Medizinische Wochenschrift

Volumn 128, Issue 6, 2003, Pages 281-287

  Scheller, Bruno ^a,b   Hennen, B ^a   Bohm M ^a   Nickenig, G ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LAMIFIBAN; LOTRAFIBAN; ORBOFIBAN; SIBRAFIBAN; TIROFIBAN; XEMILOFIBAN;

ACUTE DISEASE; ACUTE HEART INFARCTION; ANGINA PECTORIS; CARDIOLOGY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DIABETES MELLITUS; HEART MUSCLE ISCHEMIA; HUMAN; REVIEW; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT INDICATION;

ACUTE DISEASE; ANGINA PECTORIS; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MYOCARDIAL INFARCTION; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RISK FACTORS; STENTS; SYNDROME; THROMBOLYTIC THERAPY; TIME FACTORS;

EID: 0037423529     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-37078     Document Type: Review

References (72)

1. Antman E, Giugliano R, Gibson C et al. Abciximab Facilitates the Rate and Extent of Thrombolysis. Results of the Thrombolysis In Myocardial Infarction (TIMI) 14 Trial. Circulation 1999; 99: 2720-2732
2. Antman E, Louwerenburg H, Baars H et al. for the ENTIRE-TIMI 23 Investigators. Enoxaparin as Adjunctive Antithrombin Therapy for ST-Elevation Myocardial Infarction Results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial. Circulation 2002; 105: r27-r34
3. Berkowitz SD, Harrington RA, Rund MM, Tcheng JE. Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy. Circulation 1997; 95: 809-813
4. Bertrand ME et al. Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation. Eur Heart J 2000; 21: 1406-1432
5. Bhatt DL, Marso SP et al. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol 2000; 35: 922-928
6. Boersma E et al. Platelet glycoprotein IIb/IIIa-receptor inhibition in non-ST-elevation acute coronary syndromes. Circulation 1999; 100: 2045-2048
7. Boersma E, Harrington RA, Moliterno DJ et al. Platelet glycoprotein IIb/IIIa-inhibitors in acute coronary syndromes. Lancet 2002; 359: 189-198
8. Brener SJ, Barr LA, Burchenal JE et al. Randomized, Plazebo-controlled trial of platelet glycoprotein IIb/IIIa-blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation 1998; 98: 734-741
9. Cannon CP et al. Randomized trial of an oral platelet glycoprotein IIb/IIIa-antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction. Circulation 1998; 97: 340-349
10. Cannon CP, McCabe CH, Wilcox RG et al. Oral glycoprotein IIb/IIIa-inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation 2000; 102: 149-156
11. Cannon CP, Weintraub WS et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa-inhibitor tirofiban. N Engl J Med 2001; 344: 1879-1887
12. Chew DP, Bhatt DL, Sapp S, Topol E. Increased mortality with oral platelet glycoprotein IIb/IIIa-antagonists. A meta-analysis of phase III multicenter randomised trials. Circulation 2001; 103: 201-206
13. Coller BS, Peerschke El, Scudder LE, Sullivan CA. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest 1983; 72: 325-338
14. Collet JP, Montalescot G, Lesty C et al. Effects of Abciximab on the Architecture of Platelet-Rich Clots in Patients With Acute Myocardial Infarction Undergoing Primary Coronary Intervention. Circulation 2001; 103: 2328-2331
15. Combining thrombolysis with the platelet glycoprotein IIb/IIIa-inhibitor lamifiban. results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) trial. J Am Coll Cardiol 1998; 32: 2003-2010
16. Comparative 30-day economic and clinical outcomes of platelet glycoprotein IIb/IIIa-inhibitor use during elective percutaneous coronary intervention. Prairie ReoPro versus Integrilin Cost Evaluation (PRICE) Trial. Am Heart J 2000; 141: 402-9
17. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin, the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001; 358: 605-613
18. Fuster V, Badimon L et al. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med 1992; 326: 242-250
19. Gawaz M, Neumann FJ, Schomig A. Evaluation of platelet membrane glycoproteins in coronary artery disease. Circulation 1999; 99: E1-E11
20. Gibson CM, Goel M, Cohen DJ et al. Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or Plazebo during angioplasty in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. J Am Coll Cardiol 1998; 32: 28-34
21. Grines CL, Cox DA, Stone GW et al. Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med 1999; 341: 1949-56
22. Harrington RA, Armstrong PW et al. Dose-finding, safety, and tolerability study of an oral platelet glycoprotein IIb/IIIa-inhibitor, Iotrafiban, in patients with coronary or cerebral atherosclerotic disease. Circulation 2000; 102: 728-735
23. Hofmann R, Kerschner K, Steinwender C, Kypta A, Bibl D, Leisch F. Abciximab bolus injection does not reduce cerebral ischemic complications of elective carotid artery stenting: a randomized study. Stroke 2002; 33: 725-727
24. IMPACT Investigators. Randomised Plazebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet 1997; 349: 1422-1428
25. Inhibition of platelet glycoprotein IIb/IIIa-with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa-in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med 1998; 339: 436-443
26. Jong P, Cohen EA, Batchelor W et al. Bleeding risks with abciximab after full-dose thrombolysis in rescue or urgent angioplasty for acute myocardial infarction. Am Heart J 2001; 141: 218-225
27. Kereiakes DJ, Essell JH, Abbottsmith CW, Broderick TM, Runyon JP. Abciximab-associated profound thrombocytopenia. Am J Cardiol 1996; 78: 1161-1163
28. Kleiman NS, Ohman EM, Califf RM et al. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial infarction (TAMI) 8 Pilot Study. J Am Coll Cardiol 1993; 22: 381-389
29. Knight DM et al. The immunogenicity of the 7E3 murine monoclonal Fab antibody fragment variable region is dramatically reduced in humans by substitution of human for murine constant regions. Mol Immunol 1995; 32: 1271-1281
30. Lage MJ, Barber BL, McCollam PL et al. Impact of abciximab versus eptifibatide on length of hospital stay for PCI patients. Cath Card Int 2001; 53: 296-303
31. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa-receptors in cardiovascular medicine. N Engl J Med 1995; 332: 1553-1559
32. Lincoff AM et al. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa-receptors. Evaluation of Platelet IIb/IIIa-Inhibition in Stenting Investigators. N Engl J Med 1999; 341: 319-327
33. Lincoff AM, Tcheng JE, Califf RM et al. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa-blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa-blockade. Circulation 1999; 99: 1951-1958
34. Lincoff AM, Mark DB, Tcheng JE, Califf RM, Bala MV, Anderson KM, Davidson-Ray L, Knight JD, Cabot CF, Topol EJ et al. Economic assessment of platelet glycoprotein IIb/IIIa-receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization: results from the EPILOG randomized trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa-blockade. Circulation 2000; 102: 2923-2929
35. Marso SP, Lincoff AM, Ellis SG et al. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa-inhibitor for stenting trial) diabetic substudy. Circulation 1999; 100: 2477-2484
36. Matsuno H et al. Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation. Circulation 1994; 90: 2203-2206
37. Mehta SR, Yusuf S, Peters RJ et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527-533
38. McCollam PL, Lage MJ, Bala M. A comparison of total hospital costs for percutaneous coronary intervention patients receiving abciximab versus tirofiban. Catheter Cardiovasc Interv 2001; 54: 152-157
39. Montalescot G et al. Platelet glycoprotein IIb/IIIa-inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001; 344: 1895-1903
40. Neumann FJ et al. Effect of Glycoprotein IIb/IIIa-Receptor Blockade on Recovery of Coronary Flow and Left Ventricular Function After the Placement of Coronary-Artery Stents in Acute Myocardial Infarction. Circulation 1998; 98: 2695-2701
41. Neumann FJ et al. Effect of glycoprotein IIb/IIIa-receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol 2000; 35: 915-921
42. Newby LK, Ohman EM, Christenson RH et al. Benefit of glycoprotein IIb/IIIa-inhibition in patients with acute coronary syndromes and troponin t-positive status: the paragon-B troponin T substudy. Circulation 2001; 103: 2891-2896
43. Ohman EM, Kleiman NS et al. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa-integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, Plazebo-controlled, dose-ranging trial. IMPACT-AMI Investigators. Circulation 1997; 95: 846-854
44. O'Neill WW, Serruys P, Knudtson M et al. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of Oral Xemilofiban in Controlling Thrombotic Events. N Engl J Med 2000; 342: 1316-24
45. O'Shea JC, Hafley GE, Greenberg S et al. Platelet glycoprotein IIb/IIIa-integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial. JAMA 2001; 285: 2468-2473
46. PRISM Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM). N Engl J Med 1998; 338: 1498-1505
47. PRISM-PLUS Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa-receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS). N Engl J Med 1998; 338: 1488-1497
48. Qureshi AI, Suri MF, Ali Z et al. Carotid angioplasty and stent placement: a prospective analysis of perioperative complications and impact of intravenously administered abciximab. Neurosurgery 2002; 50: 466-473
49. Randomised Plazebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina. the CAPTURE Study. Lancet 1997; 349: 1429-1435
50. Roffi M, Chew D, Mukherjee D et al. Platelet Glycoprotein IIb/IIIa Inhibitors Reduce Mortality in Diabetic Patients With Non-ST-Segment-Elevation Acute Coronary Syndromes. Circulation 2001; 104: 2767-2771
51. Ryan TJ et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. Circulation 1999; 100: 1016-1030
52. Shattil SJ. Function and regulation of the β3 integrins in hemostasis and vascular biology. Thromb Haemost 1995; 74: 149-155
53. Simoons ML. Effect of glycoprotein IIb/IIIa-receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet 2001; 357: 1915-1924
54. Stone G, Grines C, Cox D et al. for the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators. Comparison of Angioplasty with Stenting, with or without Abciximab, in Acute Myocardial Infarction. N Engl J Med 2002; 346: 957-966
55. Task Force of the European Society of Cardiology. Management of stable angina pectoris. Europ Heart J 1997; 18: 394-413
56. Tcheng JE, Ellis SG, George BS et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa-integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 1994; 90: 1757-1764
57. The EPIC Investigators. Us of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa-receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-961
58. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa-receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336: 1689-1696
59. The ERASER Investigators. Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study). Circulation 1999; 100: 799-806
60. Topol EJ, Califf RM, Weisman HF et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa-integrin for reduction of clinical restenosis. results at six months: The EPIC Investigators. Lancet 1994; 343: 881-886
61. Topol EJ, Ferguson JJ et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa-Inhibition for Prevention of Ischemic Complication. JAMA 1997; 278: 479-484
62. Topol EJ, Mark DB et al. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa-blockade in patients undergoing coronary stenting, results from a multicentre randomised trial. EPISTENT Investigators: Evaluation of Platelet IIb/IIIa-Inhibitor for Stenting. Lancet 1999; 354: 2019-2024
63. Topol EJ, Yadav JS. Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation 2000; 101: 570-580
64. Topol EJ, Moliterno DJ et al. Comparison of two platelet glycoprotein IIb/IIIa-inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001; 344: 1888-1894
65. Topol EJ The GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa-inhibition. Lancet 2001; 357: 1905-1914
66. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group. Circulation 2000; 101: 2788-2794
67. Turpie AG, Antman EM. Low-molecular-weight heparins in the treatment of acute coronary syndromes. Arch Intern Med 2001; 161: 1484-1490
68. van den Merkhof LF, Zijlstra F, Olsson H et al. Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty. Results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) pilot study. J Am Coll Cardiol 1999; 33: 1528-1532
69. Weintraub WS, Culler S et al. Economic impact of GPIIB/IIIA-blockade after high-risk angioplasty: results from the RESTORE trial Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. J Am Coll Cardiol 1999; 34: 1061-1066
70. Willerson JT, Golino P, Eidt J, Campbell WB, Buja LM. Specific platelet mediators and unstable coronary artery lesions. Circulation 1989; 80: 198-205
71. Yusuf S, Zhao F, Mehta SR et al. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502
72. Zhu MM, Feit A, Chadow H, Alam M, Kwan T, Clark LT. Primary stent implantation compared with primary balloon angioplasty for acute myocardial infarction: a meta-analysis of randomized clinical trials. Am J Cardiol 2001; 88: 297-301